Radiotherapy or Imiquimod in Complex Lentigo Maligna (RADICAL)
A Randomised Controlled Multicentre Trial of Imiquimod Versus Radiotherapy for Lentigo Maligna (LM) When Staged Surgical Excision With 5mm Margins is Not Possible, is Refused, or Fails
Sponsor: Melanoma Institute Australia
This PHASE3 trial investigates Lentigo Maligna and is currently completed. Melanoma Institute Australia leads this study, which shows 14 recorded versions since 2015 — indicating substantial longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.
Status Flow
Change History
14 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE3
Status: Unknown Status → Completed
-
May 2024 — Jul 2024 [monthly]
Unknown Status PHASE3
Status: Active Not Recruiting → Unknown Status
-
May 2022 — May 2024 [monthly]
Active Not Recruiting PHASE3
Status: Recruiting → Active Not Recruiting
-
May 2021 — May 2022 [monthly]
Recruiting PHASE3
▶ Show 9 earlier versions
-
Feb 2021 — May 2021 [monthly]
Recruiting PHASE3
-
Jan 2021 — Feb 2021 [monthly]
Recruiting PHASE3
-
Oct 2019 — Jan 2021 [monthly]
Recruiting PHASE3
-
Aug 2019 — Oct 2019 [monthly]
Recruiting PHASE3
-
Nov 2018 — Aug 2019 [monthly]
Recruiting PHASE3
-
Aug 2018 — Nov 2018 [monthly]
Recruiting PHASE3
-
Jun 2018 — Aug 2018 [monthly]
Recruiting PHASE3
-
Feb 2017 — Jun 2018 [monthly]
Recruiting PHASE3
-
Jan 2017 — Feb 2017 [monthly]
Recruiting PHASE3
First recorded
Aug 2015
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Melanoma Institute Australia
- Melanoma and Skin Cancer Trials Limited
For direct contact, visit the study record on ClinicalTrials.gov .